Gabelli Funds Portfolio Manager Jeff Jonas in Reuters

J&J profit edges past Street view after deals delay Stelara competition

Johnson & Johnson (JNJ.N), opens new tab on Tuesday reported quarterly results just above Wall Street expectations, helped by strong sales of its blockbuster psoriasis drug Stelara, which is expected to face fresh U.S. competition from biosimilar versions next year.

Read more here: